Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has granted de novo marketing authorization for Avulux lenses, a new device category designed to reduce light sensitivity in migraine patients aged 12 and older. The lenses filter specific wavelengths of light linked to migraine discomfort. They're meant to complement — not replace — existing migraine treatments.
The FDA has granted de novo marketing authorization to Avulux lenses, establishing a brand-new device category: "light attenuation lenses for migraine-associated light sensitivity." This is the first time a lens has been formally classified and authorized specifically for this purpose, giving patients, eye care providers, and commercial partners a clear framework for its use.
The lenses work by blocking light at two specific wavelengths — 480 nm (high blue range) and 590 nm (red/amber range) — that are thought to trigger or worsen migraine-related light sensitivity. Available with or without a prescription, they're intended for people aged 12 and older with episodic migraine and are meant to be used alongside existing treatments, not as a standalone solution.
Key Takeaways:
Why it matters: For the millions of migraine sufferers who experience debilitating light sensitivity, this FDA-authorized option offers a non-pharmacological, adjunct tool — and its formal classification paves the way for broader clinical adoption and insurance conversations.
